Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma

[1]  P. McCue,et al.  Phase i study of intravesical vaccinia virus as a vector for gene therapy of bladder cancer. , 2001, The Journal of urology.

[2]  S. Mukherjee,et al.  Cytokine gene therapy or infusion as treatment for solid human cancer. , 1998, Journal of immunotherapy.

[3]  Geoffrey L. Smith,et al.  Antibodies against vaccinia virus do not neutralize extracellular enveloped virus but prevent virus release from infected cells and comet formation. , 1997, The Journal of general virology.

[4]  B. Acres,et al.  Intratumoral injection of GM-CSF gene encoded recombinant vaccinia virus elicits potent antitumor response in a mixture melanoma model. , 1997, Cancer gene therapy.

[5]  H. Young,et al.  Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[6]  J. Schlom,et al.  Phase I study of recombinant CEA vaccinia virus vaccine with post vaccination CEA peptide challenge. , 1996, Human gene therapy.

[7]  J. Gralow,et al.  Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines , 1996 .

[8]  F. Nathan,et al.  Gene therapy for human cancer: an essay for clinicians. , 1996, Seminars in oncology.

[9]  L. Eisenlohr,et al.  Intravesical gene therapy: in vivo gene transfer using recombinant vaccinia virus vectors. , 1994, Cancer research.

[10]  E. Jaffee,et al.  Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[11]  J. Edmonson,et al.  Cutaneous reactions to granulocyte-monocyte colony-stimulating factor. , 1992, Archives of dermatology.

[12]  D. Pardoll,et al.  Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. , 1991, Science.

[13]  B. Moss,et al.  Vaccinia virus: a tool for research and vaccine development , 1991, Science.

[14]  P. Greenberg,et al.  Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein , 1991, The Lancet.

[15]  R. Kamen,et al.  The human hematopoietic colony-stimulating factors. , 1987, Science.

[16]  B. Moss,et al.  General method for production and selection of infectious vaccinia virus recombinants expressing foreign genes , 1984, Journal of virology.

[17]  R. Prehn,et al.  Immunity to methylcholanthrene-induced sarcomas. , 1957, Journal of the National Cancer Institute.

[18]  H. Maguire,et al.  Cellular vaccine therapies for cancer. , 1998, Cancer treatment and research.

[19]  K. Foon,et al.  Biological and Hormonal Therapies of Cancer , 1998, Cancer Treatment and Research.

[20]  J. Palazzo,et al.  Immunohistochemical localization of p21(WAF1/CIP1) in normal, hyperplastic, and neoplastic uterine tissues. , 1997, Human pathology.

[21]  J. Gralow,et al.  Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines. , 1996, Blood.

[22]  R. Zinkernagel,et al.  Vaccination with two different vaccinia recombinant viruses: long-term inhibition of secondary vaccination. , 1993, Vaccine.

[23]  Fulvio Mavilio,et al.  Gene therapy , 1993, Nature.

[24]  Vaccinia (smallpox) vaccine. Recommendations of the Immunization Practices Advisory Committee (ACIP) , 1991, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[25]  F. Fenner.  Smallpox and its eradication , 1988 .

[26]  B. Moss,et al.  Vaccinia VirusExpression Vector: Coexpression of1-Galactosidase Provides Visual Screening ofRecombinant VirusPlaques , 1985 .